Amicus Therapeutics, Inc. (FOLD) Reaches $9.60 After 8.00% Down Move, Profile of 2 Analysts Covering AEGON N.V. (ADR) (AEG)

June 20, 2017 - By Peter Erickson

Among 7 analysts covering Aegon N.V. (NYSE:AEG), 2 have Buy rating, 1 Sell and 4 Hold. Therefore 29% are positive. Aegon N.V. had 10 analyst reports since August 20, 2015 according to SRatingsIntel. The stock of AEGON N.V. (ADR) (NYSE:AEG) has “Neutral” rating given on Tuesday, June 28 by JP Morgan. The firm earned “Buy” rating on Thursday, September 24 by Goldman Sachs. The stock has “Underweight” rating by Barclays Capital on Wednesday, June 29. The rating was upgraded by Deutsche Bank on Thursday, August 27 to “Hold”. The company was upgraded on Wednesday, January 20 by ING Group. As per Thursday, August 20, the company rating was downgraded by TheStreet. The stock of AEGON N.V. (ADR) (NYSE:AEG) earned “Hold” rating by Societe Generale on Thursday, October 13. As per Thursday, December 1, the company rating was downgraded by ING Group. As per Wednesday, January 11, the company rating was upgraded by Societe Generale. The company was downgraded on Thursday, December 10 by RBC Capital Markets. See AEGON N.V. (ADR) (NYSE:AEG) latest ratings:

11/01/2017 Broker: Societe Generale Old Rating: Hold New Rating: Buy Upgrade

The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) is a huge mover today! About 3.89M shares traded or 31.86% up from the average. Amicus Therapeutics, Inc. (NASDAQ:FOLD) has risen 12.45% since June 20, 2016 and is uptrending. It has underperformed by 4.25% the S&P500.The move comes after 5 months negative chart setup for the $1.44B company. It was reported on Jun, 20 by Barchart.com. We have $8.83 PT which if reached, will make NASDAQ:FOLD worth $115.20 million less.

Amicus Therapeutics, Inc. is a biotechnology company. The company has market cap of $1.44 billion. The Firm is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. It currently has negative earnings. The Company’s lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for Fabry disease.

Investors sentiment decreased to 1.24 in Q4 2016. Its down 0.25, from 1.49 in 2016Q3. It fall, as 27 investors sold Amicus Therapeutics, Inc. shares while 32 reduced holdings. 25 funds opened positions while 48 raised stakes. 151.10 million shares or 5.89% more from 142.70 million shares in 2016Q3 were reported. Axa accumulated 2.17M shares. Artal Grp Inc Sa holds 0.19% or 1.75M shares in its portfolio. Moreover, Tekla Cap Management Ltd Liability Corp has 0.09% invested in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 418,730 shares. Franklin Resource owns 1.89M shares for 0% of their portfolio. Geode Limited Company, a Massachusetts-based fund reported 1.12M shares. 15,100 were reported by Pacad Limited. Hsbc Public Limited Com reported 24,543 shares. State Common Retirement Fund has invested 0% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Rhumbline Advisers holds 0% or 130,790 shares. 183,324 are held by Qs Investors Ltd Limited Liability Company. Victory Capital accumulated 4.08 million shares. Creative Planning has invested 0% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Td Asset Management Inc stated it has 0% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Endurant Management Lp invested in 0.46% or 225,300 shares. Kcg holds 0.01% in Amicus Therapeutics, Inc. (NASDAQ:FOLD) or 65,323 shares.

Since December 22, 2016, it had 3 insider buys, and 6 selling transactions for $101,704 activity. 189,500 shares valued at $854,835 were bought by PERCEPTIVE ADVISORS LLC on Thursday, December 22. $392,400 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares were sold by Campbell Bradley L. Do Hung had sold 29,914 shares worth $239,312. On Thursday, June 15 Barth Jay sold $300,000 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) or 30,000 shares.

Among 7 analysts covering Amicus Therapeutics (NASDAQ:FOLD), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Amicus Therapeutics had 12 analyst reports since August 18, 2015 according to SRatingsIntel. JP Morgan maintained the shares of FOLD in report on Tuesday, September 8 with “Overweight” rating. Robert W. Baird upgraded Amicus Therapeutics, Inc. (NASDAQ:FOLD) rating on Tuesday, January 24. Robert W. Baird has “Outperform” rating and $10 target. The rating was initiated by Bank of America on Wednesday, May 18 with “Buy”. The firm has “Buy” rating given on Tuesday, March 8 by Janney Capital. On Monday, October 5 the stock rating was upgraded by Chardan Capital Markets to “Buy”. Goldman Sachs initiated the stock with “Neutral” rating in Wednesday, March 30 report. Cowen & Co maintained the stock with “Buy” rating in Tuesday, September 1 report. The firm earned “Buy” rating on Tuesday, August 18 by Zacks. The rating was initiated by Robert W. Baird on Thursday, April 14 with “Neutral”. The firm earned “Outperform” rating on Monday, October 5 by Leerink Swann.

Aegon N.V. is an international life insurance, pensions and asset management company. The company has market cap of $10.24 billion. The Company’s divisions include the Americas, which includes the United States, Mexico and Brazil; the Netherlands; the United Kingdom; Central & Eastern Europe; Spain & Portugal; Asia, and Aegon Asset Management. It has a 13.2 P/E ratio. It offers protection against mortality, morbidity and longevity risks, including traditional and universal life.

About 996,302 shares traded. AEGON N.V. (ADR) (NYSE:AEG) has declined 1.40% since June 20, 2016 and is downtrending. It has underperformed by 18.10% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: